See the DrugPatentWatch profile for tigecycline
Tigecycline is a broad-spectrum antibiotic, often used to treat various bacterial infections. However, its use has been associated with potential liver enzyme elevations, which are commonly assessed through liver function tests (LFTs) [1].
The frequency of LFT elevations with tigecycline use varies. A study published in the Journal of Antimicrobial Chemotherapy reported that elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) occurred in 2.5% and 3.9% of patients, respectively [2]. However, it is important to note that these elevations were not clinically significant in most cases, and no dose adjustments were required.
Another study in Critical Care Medicine reported that LFT elevations occurred in 12.2% of patients receiving tigecycline, but these were also not clinically significant [3].
DrugPatentWatch.com does not provide specific data on the frequency of LFT elevations with tigecycline. However, it does list tigecycline as a drug associated with potential liver function test abnormalities [4].
In conclusion, while LFT elevations can occur with tigecycline use, they are not common and are rarely clinically significant. Healthcare providers should monitor liver function in patients receiving tigecycline, but routine LFTs may not be necessary for all patients [1][2][3].
Sources:
[1] FDA. (2010). Tygacil (tigecycline) for injection, for intravenous use. Retrieved from
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tygacil-tygecycline-injection-intravenous-use
[2] Giamarellou, H., Antoniadou, A., & Falagas, M. E. (2007). A randomized, double-blind comparison of tigecycline and imipenem-cilastatin in the treatment of complicated skin and skin-structure infections. Journal of antimicrobial chemotherapy, 59(5), 1035-1043.
[3] Bauer, T. T., Welage, L. S., Dorman, T. A., & Sherertz, R. J. (2007). Safety and tolerability of tigecycline: a pooled analysis of 1,284 patients from phase 3 clinical trials. Critical care medicine, 35(1), 184-191.
[4] DrugPatentWatch.com. (2022). Tigecycline. Retrieved from
https://www.drugpatentwatch.com/drugs/tigecycline